Top 10 Immunofluorescence Assay Companies

Why Is the Immunofluorescence Assay Market Expanding?

The Global Immunofluorescence Assay Market is estimated to be worth USD 3.55 billion in 2025 and is expected to reach USD 6.46 billion by 2035, expanding at a CAGR of 6.25% during the forecast period of 2026-2035. Market Research Future (MRFR) points to two co-equal demand engines: the FDA’s 2024 final rule on laboratory-developed test (LDT) oversight, which is driving laboratories toward validated commercial assay kits; and a spike in government-backed infectious-disease surveillance budgets that surpassed USD 4.2 billion in 2024 worldwide.

These forces are together driving the market away from fragmented, in-house workflows and toward standardized, commercially supported platforms. The tightening of regulations, increasing volumes in autoimmune and cancer diagnostics, and the adoption of AI-driven digital pathology are combining to provide self-reinforcing structural tailwinds that will push above-baseline growth well into the 2035 forecast horizon.

Technology is the narrative in the story. Legacy manual fluorescence microscopes, the backbone of pathology labs for decades, are being replaced by AI-powered digital pathology systems capable of whole-slide imaging and automated pattern identification. Horizon Europe, the European Commission’s research program, is dedicating more than EUR 380 million to digital diagnostics research between 2023 and 2025, which will boost uptake across EU reference laboratories. By product, instruments are expected to be the fastest-growing segment owing to growing adoption of automated slide scanners and multiplex imaging platforms.

Why Are These Companies Leading the Market?

The MRFR identifies four structural factors that define category leadership in the Immunofluorescence Assay Market: full-stack reagent-to-instrument ecosystem integration that captures both consumable recurring revenue and capital equipment sales; antibody portfolio breadth and validation depth that creates switching costs for research laboratories; digital pathology and AI-enabled image analysis capabilities that redefine throughput benchmarks; and regulatory compliance positioning – particularly FDA 510(k) and EU MDR pathways – that creates barriers to entry for new assay entrants.

Thermo Fisher Scientific is at the forefront with its Invitrogen reagent range and EVOS imaging platform, backed by USD 42.88 billion of FY2024 sales and the completed USD 3.1 billion acquisition of Olink proteomics.

Top 10 Global Immunofluorescence Assay Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading immunofluorescence assay companies globally, evaluated on the basis of revenue performance, geographic presence, technology strategy, innovation investment, and laboratory network density. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of July 2026.

*Rankings reflect MRFR's qualitative assessment of scale and market influence in the immunofluorescence assay sector. Revenue figures are drawn from SEC filings and official investor disclosures where the company is publicly traded; figures for private companies are not publicly disclosed and are marked as such. Segment revenue for immunofluorescence assay specifically is not separately reported by any of the companies profiled.

Detailed Company Profiles

1. Thermo Fisher Scientific Inc. | NYSE: TMO | Waltham, Massachusetts, USA

Thermo Fisher Scientific’s Invitrogen reagent portfolio, the biggest library of fluorescent antibody conjugates in the world, and the EVOS imaging platform, which combines digital microscopy and cell analysis workflows, position the company in the immunofluorescence assay market. The business filed with the SEC, reporting total consolidated revenue of USD 42.88 billion for fiscal year 2024 and Q4 2024 revenue of USD 11.40 billion, up 5% year-over-year.

Thermo Fisher completed the acquisition of Olink, a next-generation proteomics business, for $3.1 billion in 2024. Olink uses its Proximity Extension Assay technology to complement immunofluorescence procedures by providing high-throughput identification of protein biomarkers. The acquisition expands Thermo Fisher’s full-stack ecosystem, from providing reagents to multiplex protein measurement, presenting a barrier to entry for competitors without mass spectrometry and antibody conjugate production capabilities.

2. Danaher Corporation | NYSE: DHR | Washington, D.C., USA

Danaher operates in the immunofluorescence assay market through its Leica Biosystems division, which focuses on anatomical pathology and the acquisition of Abcam, completed in 2024 and the global leader in validated research antibodies. Danaher reported USD 23.88 billion in total consolidated revenue for fiscal year 2024, including USD 1.58 billion in research and development spending, according to SEC filings.

Danaher will acquire Abcam for roughly USD 5.7 billion (USD 24.00 per share), bringing more than 11,000 verified antibody SKUs to Danaher’s portfolio to create the most comprehensive antibody catalog in life sciences. Leica Biosystems’ BOND RX and BOND III autostainers automate immunofluorescence staining in clinical pathology labs. At the same time, Abcam’s recombinant antibody technology tackles the issue of lot-to-lot variability, one of the main causes of test failure.

3. Merck KGaA | ETR: MRK | Darmstadt, Germany

Merck KGaA is represented in the immunofluorescence test market through its Life Science business under the MilliporeSigma brand, one of the world’s major providers of research antibodies, fluorescent dyes and cell culture media. According to the company’s annual report, net sales for FY2024 were EUR 21.16 billion, EBITDA pre was EUR 6.07 billion, and R&D investment was above EUR 1.7 billion.

MilliporeSigma’s antibody collection includes more than 300,000 items, including the Anti-Fade Reagent and fluorescent secondary antibodies used in indirect immunofluorescence techniques. The company has a geographical footprint in more than 70 countries with a strong presence in European academic research institutions.

4. Olympus Corporation (Evident) | TYO: 7733 | Tokyo, Japan

Olympus’ life science branch, Evident, is active in the immunofluorescence assay industry with BX series fluorescent microscopes and cellSens imaging software used in clinical diagnostic and research labs across the world. Olympus Corporation’s annual report for the fiscal year 2024 recorded total consolidated revenue of JPY 1.01 trillion (USD 6.4 billion).

In 2022, Evident was created as an independent operating company and brought together the group’s microscope, endoscope and scientific solutions divisions under one focused management. The BX53 fluorescence microscope continues to be a clinical pathology standard for immunofluorescence-based autoimmune diagnostics, particularly for ANA and ANCA panel testing.

5. Nikon Corporation | TYO: 7731 | Tokyo, Japan

Nikon is present in the immunofluorescence assay market with its Precision Equipment and Imaging Products divisions that offer Eclipse series fluorescence microscopes and NIS-Elements image analysis software to research and clinical labs. The company’s annual report said it had posted a consolidated total revenue of JPY 677.2 billion (about USD 4.3 billion) for fiscal year 2024.

Immunofluorescence cell imaging workflows are frequently used in oncology and neurology studies, and Nikon’s Ti2-U inverted research microscope and CFI60 optical system are commonly used in this field. The company has invested in super-resolution microscopy technologies to ready its product range for next-generation multiplex immunofluorescence applications.

6. Agilent Technologies Inc. | NYSE: A | Santa Clara, California, USA

Agilent has a foothold in the immunofluorescence assay industry through its Diagnostics and Genomics Group, which provides Dako antibodies and Autostainer Link platforms for automated immunohistochemistry and immunofluorescence labeling in anatomical pathology. Agilent generated sales of USD 6.51 billion in fiscal year 2024 compared to USD 6.83 billion in fiscal year 2023, according to SEC filings.

Diagnostics and Genomics Group First Quarter FY2024 Results: Revenue of USD 407 million. Agilent’s Dako brand offers FDA-authorized antibodies for companion diagnostic applications like PD-L1 testing in non-small cell lung cancer, a high-value area where immunofluorescence meets precision oncology.

7. Carl Zeiss AG (Carl Zeiss Meditec) | ETR: AFX | Oberkochen / Jena, Germany

Carl Zeiss participates in the immunofluorescence assay market through Carl Zeiss Meditec and ZEISS Microscopy, which manufacture the Axioscan automated slide scanners and LSM confocal microscopy systems used in digital pathology and research immunofluorescence.

Carl Zeiss Meditec reported revenue of EUR 2.23 billion for fiscal year 2024/25, per its annual report, while the broader ZEISS Group generated EUR 11.90 billion. In February 2024, Carl Zeiss introduced the Axioscan 7 automated slide scanner with integrated deep-learning tissue-classification algorithms, reducing manual read times by an estimated 40%. The company invested over EUR 1.7 billion in R&D across the Group in FY2024/25.

8. bioMérieux SA | EPA: BIM | Marcy-l'Étoile, France

bioMérieux participates in the immunofluorescence assay market through its VIDAS immunoassay platform and ANCA/ANA autoimmune diagnostic panels, serving clinical laboratories in over 160 countries. The company reported total consolidated revenue of EUR 3.98 billion for fiscal year 2024, per its annual report.

bioMérieux's BIOFIRE syndromic testing portfolio and VIDAS enzyme-linked fluorescence assay (ELFA) systems are used in infectious disease diagnostics, while the company's autoimmune panel leverages immunofluorescence for antinuclear antibody screening. The company maintains strong regulatory positioning with EU MDR-compliant platforms and FDA-cleared assays.

9. Bio-Rad Laboratories Inc. | NYSE: BIO | Hercules, California, USA

Bio-Rad participates in the immunofluorescence assay market through its Life Science and Clinical Diagnostics segments, supplying fluorescent secondary antibodies, quality control reagents, and imaging systems to research and clinical laboratories. The company reported total consolidated revenue of USD 2.57 billion for fiscal year 2024, per its SEC filing, compared to USD 2.67 billion in fiscal year 2023.

Bio-Rad's quality-control reagents are used to standardize immunofluorescence assays across clinical laboratories, addressing lot-to-lot variability — a primary source of regulatory audit findings. The company's droplet digital PCR and flow cytometry portfolios complement immunofluorescence workflows in cell biology research.

10. Revvity Inc. | NYSE: RVTY | Waltham, Massachusetts, USA

Revvity participates in the immunofluorescence assay market through its Vectra Polaris multiplex imaging platform and Opal reagent portfolio, which enable simultaneous detection of up to nine tissue biomarkers in formalin-fixed paraffin-embedded samples. The company reported total consolidated revenue of USD 2.76 billion for fiscal year 2024, per SEC filings, with Life Sciences segment revenue of USD 1.40 billion and Diagnostics segment revenue of USD 1.36 billion.

Revvity was formed from the 2023 spin-off of PerkinElmer's applied sciences division, creating a pure-play life sciences and diagnostics company. The Vectra Polaris platform is specifically designed for immuno-oncology research and companion diagnostic development, positioning Revvity at the intersection of multiplex immunofluorescence and precision medicine.

M&A Activity Tracker (2023–2025)

The Immunofluorescence Assay Market has experienced targeted consolidation as life sciences tools companies pursue antibody portfolio breadth, proteomics capabilities, and digital pathology scale. Market Research Future tracks the following verified, named transactions directly relevant to the immunofluorescence assay and adjacent diagnostics markets; entries that could not be corroborated against a dated public source have been removed from this tracker rather than retained as unverified placeholders.

Key Trend. MRFR analysis identifies antibody portfolio consolidation and AI-enabled digital pathology integration as the dominant M&A and innovation themes in the immunofluorescence assay market. Danaher's Abcam acquisition and Thermo Fisher's Olink acquisition represent a dual-track strategy: Danaher is securing the upstream antibody supply chain, while Thermo Fisher is expanding downstream into multiplex protein quantification. The convergence of these strategies — combined with Carl Zeiss's AI slide scanning — suggests that the next competitive battleground will be automated, multiplex immunofluorescence platforms capable of replacing manual pathologist review.

R&D Investment & Innovation Signals

R&D and technology investment across the Immunofluorescence Assay Market has accelerated as operators invest in AI-enabled digital pathology, multiplex biomarker panels, automated staining platforms, and regulatory-compliant assay kits — addressing the primary clinical constraints of pathologist shortage, assay standardization, and diagnostic throughput that define competitive differentiation in the market.

• Thermo Fisher Scientific completed the USD 3.1 billion Olink acquisition in 2024, adding Proximity Extension Assay technology with 5,300+ validated protein biomarker targets and over 1,400 scientific publications; this proteomics capability is positioned to complement immunofluorescence workflows in precision medicine applications.

• Danaher Corporation closed the USD 5.7 billion Abcam acquisition in 2024, integrating over 11,000 validated antibody SKUs into its Leica Biosystems pathology workflow; the recombinant antibody technology addresses lot-to-lot variability, a primary source of immunofluorescence assay failure in regulated laboratories.

• Carl Zeiss AG launched the Axioscan 7 automated slide scanner in February 2024, integrating deep-learning tissue-classification algorithms that reduce manual immunofluorescence read times by an estimated 40%; the company invested over EUR 1.7 billion in R&D across the Group in FY2024/25.

• The FDA finalized the Laboratory Developed Tests (LDT) rule in May 2024, requiring phased regulatory submissions for high-risk LDTs including immunofluorescence-based autoimmune panels; this regulatory shift is pushing laboratories toward validated commercial assay kits from vendors with FDA 510(k) clearance.

• The European Commission's Horizon Europe program allocated over EUR 380 million to digital diagnostics research between 2023 and 2025, accelerating AI-enabled pathology adoption across EU reference laboratories and creating demand for DICOM-WSI compliant imaging systems.

• CMS reduced payment rates for several legacy immunofluorescence CPT codes by 4–6% in 2024, pressuring margins for low-complexity tests; laboratories are shifting toward higher-value multiplex panels to maintain revenue per requisition, favoring vendors with multiplex imaging platforms like Revvity's Vectra Polaris.

• Revvity's Vectra Polaris multiplex imaging platform enables simultaneous detection of up to nine tissue biomarkers, positioning the company at the intersection of multiplex immunofluorescence and companion diagnostic development in immuno-oncology.

• Agilent Technologies maintains FDA-cleared Dako PD-L1 companion diagnostic antibodies for non-small cell lung cancer, demonstrating the strategic value of immunofluorescence in precision oncology — a high-growth segment where assay validation and regulatory clearance create significant barriers to entry.